Depression and Serotonergic Changes during the Climacteric and Postmenopausal Stages: Hormonal Influences by García-Ríos, Rosa Isela et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Depression and Serotonergic Changes during the
Climacteric and Postmenopausal Stages: Hormonal
Influences
Rosa Isela García-Ríos, Armando Mora-Pérez and
Cesar Soria-Fregozo
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69786
Abstract
Depression is a psychiatric disorder that affects a high percentage of women. Most of 
the depression disorders turn up during the premenopause and perimenopause stages 
when the hormonal oscillations make an impact in the brain function principally on 
the serotonergic system, which is related to neurobiology of depression. 5-HT1A and 
5-HT2A receptors change on functionality and density in afferent areas related to emo-
tional modulation and increased serotonin clearance, and the binding potential of sero-
tonin transport has been related to the underlying mechanism of the depression during 
the climacteric or postmenopausal stage. Some findings have been proven on preclini-
cal studies. These studies on animals have recognized how estrogen treatment activates 
intracellular signaling pathways as mitogen-activated protein (MAP)/extracellular sig-
nal-regulated kinase (ERK), tyrosine kinase brain-derived neurotrophic factor receptor 
(TrKB), insulin-like growth factor-1 receptor (IGF-1R), phosphatidylinositol 3-kinase 
(PI3)/serine/threonine-specific protein kinase (Akt), and metabotropic glutamate recep-
tor 1 (mGluR1) which interact with the serotonergic system to allow establishment of the 
estradiol effects on mood regulation. Thus, the interaction between the woman’s repro-
ductive status and the serotonin changes could be useful to create prevention strategies, 
early diagnosis, and medical treatment of climacteric and postmenopausal women with 
depression, in order to improve their quality of life.
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1. Introduction
Depression is one of the most common psychiatric disorders that affect approximately 4.84% 
people around the world, and it is considered to be one of the principal causes of disability 
worldwide [1]. According to the Global Burden of Disease study report in 2015 [2], the high-
est rates of disability-adjusted life years (DALYs) worldwide are established on women aged 
15–49 years with 5.65%, followed by 50–69 years old women with 2.98% and 70 years old with 
1.26%. DALYs represent the years of life that are adjusted by a certain level of disability expe-
rienced during a particular period of time, related to depressive disease. It supports studies 
which demonstrate that most of the depression disorder comes out during the premenopause 
and perimenopause stages.
During the beginning of menopausal stage or in the postmenopausal stage, women are more 
susceptible to suffer depression disorder with more severe and longer symptoms [3, 4]; sever-
ity of depression has been related to the ovarian hormone oscillating levels in the premeno-
pause and very low levels in early postmenopause, specifically with estrogens [5].
The climacterium stage is a period of time that includes the perimenopause, premenopause, 
and menopause (see Figure 1); in this stage the women estrogenic oscillating, produces a dys-
function on the serotonergic neurotransmission system which is related to the high prevalence 
of depression in such stages compared with women in postmenopausal stage. However, this 
relationship seems to be controversial because not all the studies reported an increased preva-
lence of depression in the climacteric stage, when women’s groups from different ethnic cul-
tures, ages, school grade, and civil status, among others, were evaluated. These divergences 
on the clinical study results could be partially justified by different neurochemical changes 
related to the effects of estradiol on serotonergic system and the influence of these changes on 
the establishment of depression during the different stages of the climacteric period. For exam-
ple, on early premenopausal stage, there is a decrease on the 5-HT1A autoreceptors in raphe, 
which is a brain structure responsible for the serotonin (5-HT) synthesis, and an increase on 
the 5-HT1A postsynaptic receptors located on the hippocampus (both receptors enable the 
antidepressant clinically effective, as the selective inhibitors of the serotonin, e.g., the fluox-
etine) related to the high hormonal concentration compared with postmenopausal women [6]. 
Figure 1. Classification of the reproductive phases of the woman. This classification is an abstract of the reproductive 
stage of women with their approximate during. Ovaries function markers and hormonal levels can help to make a 
correct classification. Modified from [57].
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Thus, this can be related with the different antidepressant responses along the climacteric and 
postmenopausal stages.
The 5-HT2A receptors located on brain areas such as prefrontal cortex contribute on regu-
lating the release of the 5-HT to areas that modulate the amygdala reactivity, brain struc-
ture involved to the emotional regulation. Treatment with 17β-estradiol for postmenopausal 
women increases the 5-HT2A receptors in prefrontal cortex [7]. However, the possible asso-
ciation between the establishment of depression in different climacteric and postmenopausal 
stages with the 5-HT2A receptor’s activity has not been explored. Nevertheless, the preclinical 
data support the involvement of these receptors on the regulation of the depression disorder 
[8, 9].
On the other hand, in healthy postmenopausal women, there is a relation between personal-
ity features such as extroversion, aggressiveness, and neuroticism with the serotonin trans-
porter (5-HTT). 5-HTT promotes polymorphism with “s” allele, which implies 5-HTT low 
expression and an increase in the impulsivity. Likewise, this trait is related with monoamine 
oxidase A (MAO-A) polymorphism that produces an increase of climacteric and depressive 
symptoms [10, 11]. In contrast, women under 50 years old with the “l” allele 5-HTT pres-
ent a better antidepressant response and neural protection against the suicide attempt [12]; 
however, this response disappears when there is a low hormonal activity during menopausal 
stage [13].
Therefore, the main objective of this work is to collect and review scientific data not only 
clinical but also preclinical data that allow us to explain the knowledge about the impact 
of hormonal change experienced during climacteric and postmenopausal stages and how it 
affects serotonin neurotransmission that may contribute to the establishment of the depres-
sion disorder and the therapeutic response to antidepressant drugs.
2. Influence of hormones on the depression disorder establishment
Some researches point out a high vulnerability to suffer depression disorder on the women 
reproductive stage, related to the hormonal changes, as a decrease on the estradiol levels 
and an increase on the follicle-stimulating hormone (FSH) levels on the perimenopausal 
[3, 14, 15] throughout different reproductive stages it is set basically two different aspects 
about the hormonal influences, principally estradiol with the increasing risk to set out 
depressive symptomatology. The first one establishes that low hormonal concentrations 
on estradiol and progesterone during the earlier follicular stage of the menstrual cycle of 
the earlier productive stage of a woman are related to premenstrual dysphoric syndrome 
characterized among some other symptoms by depression and anxiety [16]. The second one 
suggests that oscillations on the hormonal levels on early stages of the menopause transi-
tion are determinant to increase the risk of having some depressive incidences. The same 
effect is observed on women who had been throughout menopause by surgical procedure, 
thus, became on the decrease of the hormonal levels, and also there is a surgical post-period 
where they show hormonal oscillations because the renal glands try to supply the hormonal 
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lost, but it is important to mention that women who had been in a surgical procedure, such 
as oophorectomy on early age, indicate an increased probability to depression disease with 
severe and longer symptoms compared to women with a natural menopause [17].
There is a relationship at the establishment on depressive symptomatology with FSH or high 
luteinizing hormone (LH) levels and low inhibin B levels; this is a glycoprotein hormone 
secreted by teak and granulosa cells from the pre-antral and antral follicles that was respon-
sible for the inhibition of FSH production at the level of the pituitary gland and a huge vari-
ability on estradiol levels, which occur during the menopause transition that includes women 
on the premenopause and perimenopause [2, 3]. Likewise, there is a FSH levels increasing 
and an abrupt fall of the estrogen levels after 12 months of menopause considered as early 
postmenopausal [18] pattern, which is independently from the sample analyzed on the late 
premenopausal and postmenopausal stage. Those hormonal variations are related to a rise on 
depression prevalence for 10 years before and 8 years after the last menstrual cycle and fall on 
the late postmenopausal period [4]. The above suggests that alterations in the feedback of the 
hypothalamic-pituitary-gonadal axis consequence of changes on the concentrations of ovar-
ian hormone through the climacteric and postmenopausal stages, carry out a fundamental 
place on women’s emotional stability, through the regulation of brain plasticity and neuro-
chemical changes.
It has been established an association between a delay in appearance of menopause transition, 
in a period of two more years than average with 2% of decrease on the risk of a depression 
disease during the postmenopause, and also a reduction of the 50% to suffer depression dis-
ease on women who have menopause after 40 years old compared with early menopause on 
women before that age. It is suggested that those findings could be attributed to longer expo-
sure to the endogenous estrogens that develop a neural protection and antidepressive effect 
[19]. This effect seems to be associated with the cerebral changes that induce the hormonal 
diminution according to the age of the woman.
The antidepressant effect on hormone replacement therapy (HRT) or estrogenic therapy on 
menopausal women is controversial. The estrogen supply such as 17β-estradiol (100 μg/day) has 
a lack of antidepressant effects on depressed women during the postmenopausal period on the 
late stage; it is to say that, 17 years after the menopausal stage, they show a FSH (≥40 pg/ml) and 
estradiol (≤19.7 pg/ml) hormonal concentrations [20]. This lack of antidepressant effect is also 
observed in postmenopausal women in the early phase, approximately 6 months to 3 years after 
menopause, with hormonal concentrations of FSH ≥ 35 pg/ml and estradiol ≤ 40 pg/ml, when 50 
μg/day or 84 μg/day of estradiol was administered [7, 21]. The loss of estrogen efficacy against 
depression in women with postmenopausal may be associated with the downregulation of α- 
and β-estrogenic receptors at the brain level, caused by continued decrease of plasma estradiol 
concentrations. In contrast, antidepressant effects have also been reported in postmenopausal 
women with replacement treatments with bioidentical hormones (80% estriol/20% estradiol; 
0.25 to 0.5 mg) and/or progesterone (20 to 60 mg), by transdermal injection in a volume of 
1 ml/day for a period of 8 weeks. These women present an improvement in the depressive and 
anxiety symptoms according to Hamilton scales, at 2 months of treatment and annually until 
36 months. Treatment with bioidentical hormones improved the health and quality of life of 
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women without reports of adverse side effects. However, these women cursed postmenopausal, 
after an oophorectomy with a mean age of 52.3 ± 9.6 years and the time that elapsed since the 
surgery was not described, so it cannot be specified whether it was in the early or late stage of 
postmenopause [22]. This suggests that the type of molecule used for hormone replacement 
therapy and probably the age at which it is given could determine therapeutic success, a pos-
sibility that remains to be explored.
Changes in plasma levels of FSH on the establishment of depression in women with natural 
menopause are also seen in women with oophorectomy [23]; since the ovaries are removed, 
there is an abrupt cessation in the production of testosterone that is aromatized to estrogen 
and estradiol, which results in a dysfunction in the hypothalamic-pituitary-gonadal axis 
increasing FSH and LH levels, with the consequent decline of estradiol and progesterone 
levels [24]. These changes in hormone levels undergoing surgery take from 2 to 3 months to 
stabilize and are associated with a decrease in depressive symptoms [23]. Women undergo-
ing menopause induced by surgeries such as hysterectomy and/or oophorectomy increase 
up to four times the probability to suffer postsurgery depression [25]. However, women who 
have undergone some depressive episode prior to surgery report a decrease in postoperative 
depressive symptomatology [25]. This may reflect a paradoxical effect. Some of the answers 
might be in the interrelation between estrogen and the serotonergic system.
3. Serotonergic alterations during the climacteric and postmenopause 
related with depression
A study by Stein et al. [6] detected an increase on 5-HT1A receptor levels in the hippocampus 
and a decrease in the dorsal nucleus raphe of premenopausal women at early ages (24.1 ± 
2.6 years) compared to postmenopausal women (55.2 ± 4.8 years). In this same study, they 
identified higher concentrations of progesterone, estradiol, dehydroepiandrosterone sulfate 
(DHEAS), and cortisol in premenopausal women compared to postmenopausal women. This 
suggests that these hormones could be involved in the regulation of the expression of 5-HT1A 
receptors in different brain areas in women who travel through the climacteric, intervening in 
the establishment of depressive disorders of this stage, as well as in the different therapeutic 
responses to antidepressant drugs, and probably contributing to the effect of drug resistance, 
depending on the levels of receptors affected by oscillations on concentrations of hormones, 
mainly produced by the ovaries.
Studies made with positron emission tomography with [carbonyl-C11] WAY-100635 show 
that in the dorsal nucleus raphe, a structure highly involved in the regulation of serotonergic 
neurotransmission and therefore with a high density of 5-HT1A receptors, there is 1.5 times 
more 5-HT1A receptors in the luteal phase than in the follicular phase in healthy women, 
whereas this proportion is not observed in women with premenstrual dysphoric disorder 
[26], so a dysfunction like this could be a factor underlying to the establishment of depressive 
symptoms. Although Drevets et al. [27] reported a reduction in 5-HT1A receptors in the raphe 
(41.5%) and neocortical and limbic areas (25–33%) in depressed patients [27]. In this study the 
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sex of the patients was not discriminated, and only from 4 to 7% of the patients were women 
and do not described the age neither conditions of the reproductive phase, so these results 
should be taken with reservation.
Moses-Kolko et al. [28] reported that in depressed women going through premenopause 
and postmenopause, there is a 15% decrease in 5-HT1A receptors in the orbitofrontal cortex 
compared to adult men with depression. The foregoing after performing an endocrine stan-
dardization to minimize the influence introduced by endogenous hormonal fluctuations and 
reproductive stage. They also detected an increase in the potential binding to 5-HT1A recep-
tors in women, as age increases. They estimate that there is a 4.5% reduction per decade of 
age in the number of 5-HT1A receptors in the raphe in women. The 5-HT1A receptors have 
an age-dependent increase in neocortical regions in women, associated with decreased estro-
gen. In the same study, they identified that increase in 5-HT2A receptors is associated with 
the establishment of disorders such as neurosis, depression, suicide, and eating disorders 
[28], suggesting that age tends to reduce these receptors, since they are expressed in the neu-
ropil of pyramidal neurons located mainly in the neocortex which are related to the release 
of glutamate and gamma-aminobutyric acid (GABA) regulating the postsynaptic excitatory 
impulses that project to the hippocampus and spinal cord neurons [29]. So, it is hypothesized 
that its reduction associated with age may be related to sleep disorder, cognition, and mood 
disorders [30].
4. Serotonergic changes associated to antidepressants and hormone 
replacement in the climacteric and postmenopause
The HRT in women undergoing climacteric, with 17β-estradiol by means of transdermal 
patches at a mean dose of 93 μg/day, causes an increase in plasma levels of estradiol from 14.7 
pg/ml at baseline versus 176.5 pg/ml, after 10.2 weeks of treatment. This increase in estrogen 
levels has been related to the establishment of antidepressant effects after HRT [7]. However, 
several studies suggest that estrogens have the capability to produce a modulating effect on 
the serotonergic system that contributes to the establishment of the antidepressant effect (see 
Table 1).
In surgically postmenopausal women (58.4 age and 7.5 years after oophorectomy) and, there-
fore, with very low plasmatic concentrations of estradiol, the treatment with estradiol reduces 
the potential binding of 5-HTT in brain structures, such as in the amygdala, in the frontal 
cortex, and in various cortical regions. While the treatment with estradiol and testosterone 
reduces it in the parahippocampal gyrus, insular cortex, caudate nucleus, and thalamus [31]. 
Hence, the hormonal treatment reduces the efficiency of 5-HTT and increases the availability 
of 5-HT in the synaptic cleft on structures involved in the emotion modulation. This fact 
could be associated to an improvement in depressive symptomatology of these women mea-
sured with Beck Depression Inventory test [31]. However, some studies indicate that estrogen 
therapy in postmenopausal women does not produce antidepressant effects [21, 24], prob-
ably due to the downregulation of estrogenic receptors, associated with chronic decrease of 
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Changes associated to condition without pharmacological treatment
Condition (average age) Serotonergic system Hormonal changes References
Premenopausal women 
(24.1 ± 2.6 years) vs. 
postmenopausal women 
(55.2 ± 4.8 years)
↑ 5HT1A receptor levels in the 
hippocampus
↓ 5HT1A receptor levels in the 
dorsal raphe
↑ Levels of progesterone, estradiol, 
dehydroepiandrosterone sulfate 
(DHEAS), and cortisol
[6]
Premenopausal depressed 
women (<50 years)
Postmenopausal depressed 
women (>50 years)
↓ Postsynaptic 5-HT1A receptors 
in neocortical regions
Increasing age was associated 
with↑ postsynaptic 5-HT1A 
receptor binding potential in 
neocortical regions
Significant decline in 5HT2A 
receptor binding potential 
relative to age (8% per decade)
Low estradiol concentrations 
and low 5HT1A receptor binding 
potential
[28]
Changes associated to condition and estrogen replacement therapy
Condition (average age) Serotonergic system changes Regimen of treatment and/or 
changes associated to treatment
References
Surgically postmenopausal 
women (58.4 ± 4.7 years)
Hysterectomy and bilateral 
oophorectomy
↓ The binding potential of 
5-HTT in the amygdala, 
parahippocampal gyrus, insular 
cortex, and frontal cortex and in 
various cortical regions
Positive correlation between 
estradiol levels and the binding 
potential of 5-HTT in putamen, 
frontal cortex, and amygdala
Negative correlation between 
testosterone levels and the binding 
potential of 5-HTT in the anterior 
cingulate cortex, hippocampus, 
caudate nucleus and thalamus
[31]
Postmenopausal women 
(54.5 years, 44–68 age 
range)
↑ 5-HT2A serotonergic receptors 
mainly in brain areas such as the 
right inferior prefrontal cortex, 
anterior cingulate cortex, and 
medial and inferior frontal gyrus
Transdermal patch (17β-estradiol, 
0.075–0.15 mg; mean dose=0.084 
mg for a mean of 10.2 weeks
Negative correlation between 
estradiol levels and 5HT2A 
receptors
[7]
Postmenopausal women 
(55 ± 4.8)
No significant differences in 
5-HT1A binding potential values
Combination 17β-estradiol 
valerate (Progynova® 21 mite; 
2 mg/day, v.o.) and micronized 
progesterone (Utrogestan®, 200 
mg/day, v.o.) for 67 ± 8 days
Increase in estradiol and 
progesterone plasma levels
[56]
Female rats (2–3 months)
Five postovariectomy days
↓ The time of 5-HT1A receptor 
desensitization of 7 days with 
fluoxetine and 2 days with 
estradiol + fluoxetine
17β-Estradiol-3-benzoate (0.01 
mg/0.4 ml/kg, s.c.) plus fluoxetine 
(10 mg/2 l/kg, s.c.)
[37]
Female rats (2 months)
Two months of 
postovariectomy
↑ 5-HT level in raphe Estradiol benzoate (2.5 μg/kg/0.1 
ml, s.c., day of ovariectomy; 5 
μg/kg/0.1 ml, s.c., weekly; 20 μg/
kg/0.1 ml, s.c. day of the test) + 
Progesterone (2 mg/kg/0.1 ml, s.c., 
48 hours before the test)
[40]
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concentrations of estradiol in the postmenopausal stage. This hypothesis is based on the fact 
that estrogenic antidepressant treatment on perimenopausal women produces therapeutic 
effects [32], probably because they still have considerable concentrations of estradiol, com-
pared to postmenopausal women, which contribute that they do not present important neu-
rochemical changes on estrogen receptors. In support, depressed postmenopausal women 
treated simultaneously with the combination of antidepressant serotonin-specific reuptake 
inhibitor drugs, such as fluoxetine with estrogen, showed significantly greater improvement 
of both mood and quality of life compared to fluoxetine monotherapy [33]. Pointing out that 
estrogen by itself probably does not produce antidepressant effects, the reduction that exerts 
on the potential binding of 5-HTT is enough to increase synaptic 5-HT concentration, a syn-
ergistic effect on serotonergic system of both estrogen and fluoxetine, which contributes to 
the establishment of the antidepressant effect. Paradoxically, the combination with tibolone, 
a synthetic steroid, does not produce synergistic antidepressant effects with fluoxetine [34]. 
The above suggests that substituents on steroid molecules could be a determinant in the 
potential interrelation in therapeutic efficacy between steroids and the serotonergic system.
On the other hand, some studies observed an increase on hypersensibility of postsynaptic 
5-HT2A receptors on the basis of neurobiological depression [35, 36]. The 5-HT2A receptor 
is related to regulating the 5-HT release on the protection of neurons which are located on 
the prefrontal cortex, thus, to help the regulation easier to the amygdala’s reaction and some 
other behaviors related. The administration of 150 mg/day of clomipramine for 3 weeks, tri-
cyclic antidepressant, results a descend of 5-HT2A receptor’s occupation on neocortex area, 
Female rats (1–2 months)
2–3 weeks of 
postovariectomy
Slowing of the 5-HT clearances, 
as well as an inhibition of the 
ability of fluvoxamine (SSRI 
antidepressant) to slow the 
clearance of 5-HT
Acute administration of both 
17β-estradiol in the CA3 region 
of the hippocampus and systemic 
administration of estradiol 
benzoate (25 μg/100 μl, s.c., 48 
hours before progesterone) + 
progesterone (500 μg/100 μl, s.c., 
24 hours before the test)
[41]
Female rats (2–3 months)
2–3 weeks postovariectomy
Canceled the antidepressive-like 
effect of fluvoxamine (10 mg/kg) 
in forced swim test
Estradiol benzoate (25 μg/100 μl, 
s.c., 74–75 hours before the test 
and 24 hours before progesterone) 
+ progesterone (500 μg/100 μl, s.c., 
24 or 74–75 hours before the test)
[42]
Female rats (4 months)
Two weeks of 
postovariectomy
Inhibits the 5-HTT Estradiol (20 pmol) in the CA3 
region of the hippocampus but not 
in 10 months in females, even at 
<40 pmol doses
[51]
5-HTT, serotonin transporter; 5-HT, 5-hidroxytriptamine; ↑, increase; ↓, decrease; SSRI, selective serotonin reuptake 
inhibitors
Table 1. Clinical and preclinical studies of the relation between serotonergic system and hormones.
Changes associated to condition and estrogen replacement therapy
Condition (average age) Serotonergic system changes Regimen of treatment and/or 
changes associated to treatment
References 
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calculated by positron emission tomography (PET) which coincide with depression scores 
significantly improved, denoting the probability of the clomipramine’s interaction with those 
receptors or may cause modified signal mechanism of these receptors [37].
There is a relationship with ovarian hormone and the 5-HT2A receptors. Kugaya et al. [7] 
developed a study on postmenopausal women, classified by the concentrations of FSH ≥30 
UI/L. Those women were treated with 17β-estradiol HRT for almost 3 months; by PET that 
5-HT2A serotonin receptors increased principally on brain areas such as prefrontal cortex and 
anterior cingulate cortex, related to increase of plasmatic estradiol density, this study did not 
mark any changes related to the effects on the mood but could be the result related to the test 
characteristics and the few subjects of study [7].
5. Preclinical studies of serotonergic changes associated with 
hormones  and ovariectomy
Studies made in rodents have also shown the interrelation between estrogen and serotonergic 
system. Coadministration of estradiol with fluoxetine has been shown to contribute to 5-HT1A 
receptor desensitization [38], which is associated with antidepressant effect in humans and 
in rats evaluated in behavioral despair models [38]. In addition, this combination of estradiol 
with fluoxetine inhibits 5-HTT and increases de novo brain serotonin synthesis by activating 
tryptophan hydroxylase enzyme [39]. At the same time, it increases the number and sensitiv-
ity of the 5-HT1A receptors, mainly in the dorsal nucleus raphe of rats. This could be related 
to the antidepressant effect produced by estradiol.
It has also been detected that acute administration of estradiol on ovariectomized rats 
increased the turnover of serotonin, by increasing serotonin and its metabolite, 5-hydroxyin-
doleacetic acid (5-HIAA) in amygdale and striatum involved in the mood regulation. While 
chronic for 16 days, estradiol and progesterone administration has been found to increase 
serotonin mainly in the dorsal raphe of the ovariectomized rats [40].
Benmansour and collaborators’ research group [41] has explored the signaling mechanisms 
involved in the interaction of estradiol and serotonergic systems in rats. Both acute adminis-
tration of 17β-estradiol in the CA3 region of the hippocampus and systemic administration of 
estradiol benzoate cause slowing of the 5-HT clearances, as well as an inhibition of the ability of 
fluvoxamine to slow the clearance of 5-HT [41]. These effects are mediated by estrogen receptors 
α and β. The slowing of the 5-HT clearance was due to activation of β-estrogen and/or GPR30. 
Meanwhile, the blockade of fluvoxamine’s inhibitory effect on 5-HT clearance was mediated by 
α-estrogen [42]. Both of them used different signaling mechanisms. The estradiol-induced slow-
ing of serotonin clearance by means of activation of receptors of β-estrogen required MAPK/
ERK1/2 signaling pathways and involved interactions both with tyrosine kinase BDNF receptor 
(TrKB) and insulin-like growth factor-1 receptor (IGF-1R). The effect of estradiol to preven-
tion of the ability of fluvoxamine to slow serotonin clearance, through receptors of α-estrogen, 
required MAPK/ERK1/2 and PI3K/Akt signaling pathways as well as interactions with both 
IGF-1R and mGluR1 [43]. All these ways are etiologically implied to depression.
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In this context, the ERK signaling cascade is activated by antidepressant clinically effec-
tive as fluoxetine [44] and the systemic blockade of the MAPK pathway in mice produced 
depressive-like behavior in several animal models of experimental depression as well as 
inhibits the antidepressant effect of desipramine and fluoxetine in the forced swim test, a 
main model of depression [45]. On the other hand, the action of BDNF, which has been 
implicated in the mechanism(s) of action of the antidepressant (see Ref. [46]), is mediated 
through its high-affinity tyrosine kinase receptor B (TrkB), whose activation is required for 
antidepressant-like effect [47].
The acute intraventricular administration of IGF-1 produced antidepressant-like effects 
in mice evaluated in the tail suspension and forced swim tests [48], an effect detected 
after 3 days of the administration with participation of 5-HT [49]. The antagonism of the 
mGluR produced antidepressant-like effects in the forced swim test, probably through the 
intracellular signaling pathways described above [50]. Therefore, there is evidence about 
the interaction with the estrogens and the serotonergic system on the regulation on the 
depression disorder not only removing them but also influencing them by the other neu-
rotransmitter systems and other kinds of receptors.
We have already mentioned the difference between the plasmatic estradiol levels during the 
climacteric stage that is related to the establishment of the depression disease and the antide-
pressant responses. We have also mentioned that estradiol slows the clearance of 5-HT and at 
the same time disables the same effect produced by fluvoxamine per se. In this sense during 
the rat estrous cycle, it has been shown that both estrous and diestrus phases are character-
ized by low estradiol levels in comparison to the proestrous phase; the fluvoxamine increases 
the clearance time of 5-HT, but not in the proestrous phase [41]. Rats with 2–3 postovariec-
tomy weeks, it is observed that fluvoxamine increases the clearance time of 5-HT, the same 
effect caused by the estradiol benzoate treatment. However, the pretreatment with estradiol 
benzoate blocks the fluvoxamine effect [41].
Additionally evaluated the estradiol effect on the 5-HTT functionality, through time a clear-
ance of the 5-HT, in different ages and postovariectomy time identifying that microinjection 
of 20pmol of estradiol on CA3 region in the hippocampus to inhibit 5-HTT in young adult 
rats (4 months age) after 2 weeks from the postovariectomy, but had not effect in middle-age 
rats (10 months), even with the use of <40 pmol dosage. While fluvoxamine reduces the clear-
ance of 5-HT on rats about 10 months aged with 2 weeks, 4 and 8 months postovariectomy 
the same way as the 4 months rats [51]. Additionally, they detected that 5 μg/day of estradiol 
for 2 weeks subcutaneously via implantation of osmotic minipumps produces antidepressant 
effects on forced swim test on 4-month aged rats but not in 10-month aged rats both with 2 
weeks of postovariectomy. Nevertheless the dosage of estradiol for 10 μg/day produces an 
antidepressant effect after 2 weeks of the postovariectomy procedure, but not at 4 months of 
postovariectomy in 10-month aged rats. The same dosages produced the same antidepres-
sant effect on older rats (14 months of age) after 2 weeks of postovariectomy. The authors 
conclude that the lack of an antidepressant effect in estradiol is due to the 4-month hormone 
withdrawal and not to an age effect. Also in the same study, they reported that 2 weeks of 
treatment with sertraline, an antidepressant selective serotonin reuptake inhibitors (SSRI), on 
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rats from 4 to 10 months of age with 2 weeks, 4 months, and 8 months of postovariectomy 
produce antidepressant effect in the forced swim test. In this study, it is concluded that the 
age influences the potency of estradiol on the 5-HTT, but its effects were strongly reduced 
if the period of postovariectomy is longer. On the other hand, the treatment with sertraline 
inhibited the 5-HTT and produced antidepressant-like effects without affected either by age 
or length of hormonal depletion [51].
In support to clinics finding about 5-HT2A receptors above mentioned some animal studies 
it has been observed that the administration of 5-HT2A receptor antagonist, i.e., ketanserin 
(0.1 mg/kg, i.p., 14 days) produces antidepressant effects in forced swim test and anxiolytic 
effect in elevated plus-maze test both in the proestrous and estrous phases of estrous cycle, 
characterized by high concentrations of progesterone and estradiol. In contrast, produces 
anxiogenic effect in phases with reduce concentrations of estradiol [52]. It is suggested that 
5-HT2A receptors play different roles on the modulation of anxiety and depression associ-
ated with the alterations of hormonal concentrations during the ovarian cycle. In contrast, 
ketanserin administered in the same doses (0.1 mg/kg, i.p.) for 7 days in male rats produces 
an antidepressant-like effect, and together with the antidepressant fluoxetine (5 mg/kg, i.p., 
7 days), it potentiates the antidepressant effect in forced swim test [53]. This suggests that 
the effect of ketanserin on females goes beyond changes in hormonal concentrations, which 
requires exploration.
Previous searches suggest that different hormonal levels, which vary through different repro-
ductive statuses on women, may cause some changes on serotonergic system. For example, 
density and potential binding of the 5-HT1A and 5-HT2A receptors, as well as the potential 
binding of the 5-HTT in different brain structures linked to the mood changes, may contribute 
to the depression establishment. Those disruptions on the serotonergic system may influence 
or modify negatively the success of therapeutic response treated with antidepressant drugs or 
HRT; there is one possibility that must be explored.
5.1. Pharmacological response prediction: 5-HT1A and 5-HT2A receptors
Pharmacological compounds that take action on 5-HT1A receptors such as SSRI are clini-
cally effective antidepressants but require a period of 3–6 weeks of treatment to establish 
the therapeutic effects [54]. Additionally, 50 to 70% depressed patients respond to the first 
pharmacological treatment, and less than 40% get a total remission [54]. Combination of 
SSRI with 5-HT2A receptor antagonist makes the latency period shorter for the establish-
ment of antidepressant effect [55]. This fact suggests that the stimulation of 5-HT1A recep-
tors by SSRI and the inactivity of 5-HT2A receptors, which are part of the serotonin release 
on limbic areas, produce synergism effect. Therefore, the alteration in the expression of 
receptors in different brain areas, associated with variations of hormones such as estra-
diol, mainly in the stages of the climacteric, can influence the pharmacological response to 
antidepressants.
There are controversial data related to regulatory mechanism, which are exerted to antide-
pressant treatments on the 5-HT1A and 5-HT2A receptor density. A study developed by 
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Kranz et al. [56] did not detect differences on the 5-HT1A receptor density on structures such 
as the hippocampus, the frontal cortex, and the raphe on postmenopausal woman [56]. After 
the administration of HRT with 17β-valerate ester alone or combined with progesterone, no 
matter the fact exist, a significant increase of estradiol and progesterone, an effect that has been 
identified on postmenopausal women [28]. This suggests that plasma concentrations of estra-
diol that are still elevated in premenopausal women compared to postmenopausal women 
seem to determine the 5-HT 1A receptor expression on the estrogenic treatment response.
6. Final comments and conclusion
Variations in the levels of ovarian hormones that occur throughout the stages of climacteric 
and postmenopause severely impact women’s mood. The depression is found mainly in 
the stages with continuous hormonal oscillations like perimenopause and premenopause. 
However, the relationship between hormonal and serotonergic systems in the climacteric 
and postmenopausal stages needs to be explored. The neurochemical and neurophysiologi-
cal modification consequence of the oscillating hormonal levels leads to alterations in the 
cerebral neurotransmission functioning, mainly on the serotonergic system of the 5-HTT, 
5-HT turnover, and 5-HT1A/5-HT2A receptors. This affects the pharmacological response to 
antidepressant treatments, both with estrogen therapy and with SSRI or tricyclic drugs in the 
different climacteric and postmenopausal stages.
The limitation on the studies have contributed to the establishment of these hypothesis 
emerged by the reduced length of women included in the studies and the wide range 
of ages which is used, because these incorporate women who are in different stages and 
different reproductive status and also women going through induced oophorectomy post-
menopausal on early ages. Also, the lack of quantification of the hormonal levels, princi-
pally estradiol, FSH, and the ovarian function markers such as inhibin B, antral follicle 
count, anti-Müllerian hormone, and the estradiol levels. There is a direct relationship 
between advanced age and elevated serum basal levels which is associated with poor ovar-
ian response. However, additional studies are needed to support these findings because 
it should let us categorize effectively those women on their reproductive stage. Thus, it 
allows us to establish a correct reciprocity between the serotonin changes and evaluated 
stages.
In addition, some limits in the imaging studies (e.g., PET), which are difficult to correct 
analysis on small brain structures or markers used, are not always selective to serotonin 
receptors, principally 5-HT2A receptors. It is also necessary to extend the researches related 
to serotonin changes on women with some depressant disorder, as major depression on all 
the reproductive stages, because some recent studies are only used to evaluate the symp-
tomatology improvement on menopause, as somatic, urogenital, or physiologic symptom-
atology. On the last one, the symptomatology causes low motivation but without depression 
diagnosis, which limits the exploration of the neurochemical alterations that underlay to the 
depressive disorder on many different reproductive stages.
There are two areas that have been explored yet; the first one is nonsymptomatic women, thus, 
probably related to the hormonal levels through the reproductive stages and the correlation with 
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brain serotonergic function, and also women through oophorectomies on early ages or ovarian 
failure (both under 40 years old). Women through an abrupt fall on ovarian hormone and some 
studies point out a high prevalence of depressive disorder longer and severe. Data may contrib-
ute to possible genetic factors, biological, psychosocial, and environmental, which are related to 
the establishment of the depressive disorder on different climacteric and postmenopausal stages.
In conclusion, depression associated to climacteric and postmenopausal stages involves 
changes in the serotonergic system, which includes an increase in the 5-HT clearance, turnover 
of 5-HT, and affinity of 5-HTT, as well as increased expression of 5-HT1A and 5-HT2A recep-
tors in different brain regions (i.e., prefrontal cortex and hippocampus). All these changes 
seem to be a result of the oscillations in the ovarian hormone concentration characteristics of 
the climacteric and postmenopausal stages.
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